
Assembly Biosciences (ASMB) Stock Forecast & Price Target
Assembly Biosciences (ASMB) Analyst Ratings
Bulls say
Assembly Biosciences Inc is advancing its clinical-stage programs aimed at revolutionizing the treatment landscape for hepatitis B virus (HBV) and dysbiotic microbiomes, primarily generating revenue from its HBV cure initiatives. The promising interim Phase 1b data for ABI-5366 indicates robust antiviral activity and supports progressing towards Phase 2, while Gilead's collaboration enhances financial stability and reduces risks associated with Assembly's pipeline. Additionally, the potential for innovative oral regimens to significantly expand the market for HSV treatment further solidifies Assembly’s position as a leading player in the development of next-generation antivirals.
Bears say
Assembly Biosciences Inc faces significant challenges that contribute to a negative outlook on its stock, largely stemming from clinical development risks associated with its drug candidates ABI-6250 and ABI-5366, where concerns over biomarker-driven progression and virologic endpoints persist. Additionally, reliance on Gilead as a primary strategic collaborator introduces opt-in risk, especially if Gilead delays or decides against proceeding with the programs, further complicating the company’s commercialization efforts. Assembly also confronts potential dilution risk if it seeks additional capital before achieving key opt-in or milestone events, alongside manufacturing and regulatory delays that could impede progress in its platform programs.
This aggregate rating is based on analysts' research of Assembly Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Assembly Biosciences (ASMB) Analyst Forecast & Price Prediction
Start investing in Assembly Biosciences (ASMB)
Order type
Buy in
Order amount
Est. shares
0 shares